Friday's Health Winners & Losers

Icon's(ICLR Quote) shares rose after the company announced a 2-for-1 stock split, subject to shareholder approval. The Dublin, Ireland-based provider of outsourced drug and device development will hold a general meeting of shareholders next month. Shares of Icon gained 1.1% to $69.48.

Vaccine developer Iomai(IOMI Quote) spiked 23% following an upgrade on the stock to buy from neutral. According to UBS analyst Annabel Samimy, the company is developing dosing strategies for pandemic flu treatments and a possible partnership to develop a needle-free flu vaccine that could boost the stock to $5. Shares were trading up 28.2% to $4.45.

Allscripts Healthcare Solutions(MDRX Quote) sank following a downgrade of the stock by UBS analyst Donald Hooker to reduce from neutral. UBS maintained its price target of $18. Shares were down 6% to $20.22. Separately, Allscripts said California's Riverside Physician Network has decided to use the company's TouchWorks Electronic Health Record technology to connect its network of 200 doctors.

Cancer drugmaker Celgene saw its shares move lower after investment firm Goldman Sachs initiated coverage of the stock with a neutral rating and a $50 price target. While the company has strong sales momentum and improving margins, according to biotech analyst May-Kin Ho, Celgene faces reimbursement pressures as off-label use of its drugs are under increasing scrutiny. The company's blood cancer drugs Revlimid and Thalomid also face competitive pressure from Millennium Pharmaceuticals'(MLNM Quote) Velcade. Shares fell 2.6% to $43.46.